Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
Tomsk National Research Medical Center of the Russian Academy of Sciences
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
Eli Lilly and Company
Baptist Health South Florida
ViroMissile, Inc.
Eli Lilly and Company
IntoCell, Inc
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Eli Lilly and Company
Angiex, Inc.
NiKang Therapeutics, Inc.
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
General Oncology, Inc.
Artios Pharma Ltd
Eli Lilly and Company
OncoNano Medicine, Inc.
MOMA Therapeutics
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Hummingbird Bioscience
M.D. Anderson Cancer Center
University of Kansas Medical Center
Sichuan Baili Pharmaceutical Co., Ltd.
NiKang Therapeutics, Inc.
Hunan Cancer Hospital
Nurix Therapeutics, Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Memgen, Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Cancer Trials Ireland
Ono Pharmaceutical Co. Ltd
Lyell Immunopharma, Inc.
NextPoint Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
BeiGene
AbbVie